ライフサイエンスコーパス: pharmacogenetic

1 foods remain to be evaluated in light of CYP pharmacogenetics.

2 l implementation of clopidogrel and warfarin pharmacogenetics.

3 edicine, and future clinical implications of pharmacogenetics.

4 obehavioral mechanisms of naltrexone and its pharmacogenetics.

5 h particular design features of relevance in pharmacogenetics.

6 with, previous findings in antihypertensive pharmacogenetics.

7 We provide a current review of opiate pharmacogenetics.

8 tcomes, which are of particular relevance in pharmacogenetics.

9 mechanism of action will lead to advances in pharmacogenetics.

10 could link to normal reversal learning using pharmacogenetics.

11 ashion, and by combining this with selective pharmacogenetic activation and optogenetic mapping techn

12 ns to ambient temperature changes, and their pharmacogenetic activation drives robust suppression of

13 Pharmacogenetic activation of c-Fos-labelled sleep-activ

14 Pharmacogenetic activation of Mrgprb4-expressing neurons

15 Moreover, pharmacogenetic activation of Nos1(PVH) neurons suppress

16 changes of L5 PNs are prevented by selective pharmacogenetic activation of PV+INs in the barrel corte

17 Pharmacogenetic activation of somatostatin-expressing ce

18 Pharmacogenetic activation of the mouse CT equivalent ha

19 Furthermore, pharmacogenetic activation of these neurons using design

20 antly more accurate (all p < 0.001) with the pharmacogenetic algorithm (52%) than with all other meth

21 Furthermore, we developed a new pharmacogenetic algorithm that permits the stratificatio

22 n dose stratified by genotype), and 1 formal pharmacogenetic algorithm, using both clinical and genet

23 d Clinical Effectiveness Trial Comparing Two Pharmacogenetic Algorithms and Standard Care for Individ

24 Pharmacogenetic algorithms based on regression equations

25 re the accuracy of genetic tables and formal pharmacogenetic algorithms for warfarin dosing.

26 demonstrate that racially informed warfarin pharmacogenetic algorithms perform better than tradition

27 conducting 1000 simulations of the applying pharmacogenetic algorithms to individualize dosing of wa

28 arin dose better than empiric dosing, formal pharmacogenetic algorithms were the most accurate.

29 eclinical trial design of target population, pharmacogenetic algorithms, and dosing protocols to opti

30 This study evaluated the largest pharmacogenetic AMD cohort reported to date.

31 Pharmacogenetic analysis in the placebo controlled trial

32 The authors performed a pharmacogenetic analysis of antipsychotic treatment resp

33 This study is a pharmacogenetic analysis of the effects of genetic varia

34 evalence (<2%) of most variants hinder their pharmacogenetic analysis with population sizes often ina

35 Pharmacogenetics analysis showed single nucleotide polym

36 Pharmacogenetics analysis showed that exm-rs1321744 achi

37 Of these, 15 genetic, 2 pharmacogenetic and 6 biochemical studies were included

38 lysis of candidate gene association studies, pharmacogenetic and biochemical (metabolomics) studies p

39 we found that there were not enough genetic, pharmacogenetic and biochemical studies of ADHD in adult

40 Ca(2)(+) and glutamate indicators as well as pharmacogenetic and electrical control of neurotransmitt

41 Pharmacological, pharmacogenetic and environmental approaches to prevent

42 on of neuronal CB2Rs, as shown by a combined pharmacogenetic and immunohistochemical approach.

43 sleep-wake regulation in humans and combined pharmacogenetic and neurophysiologic methods to analyze

44 in the time in therapeutic range between the pharmacogenetic and standard arm (78.8% versus 73.8%; P=

45 or candidate gene association studies, 5 for pharmacogenetics and 21 for biochemical studies.

46 ncluding histocompatibility, immunogenetics, pharmacogenetics and anthropology studies, among many ot

47 This review will focus on pharmacogenetics and pharmacogenomics and their role in

48 f AA in patients treated with TNF inhibitors.Pharmacogenetics and the inherent physiologic levels of

49 First, using pharmacogenetics and two-photon calcium imaging, we vali

50 Pharmacogenetics and, more recently, pharmacogenomics ha

51 ocompatibility, immunology, epidemiology and pharmacogenetics) and population genetics.

52 clinical pharmacology, pharmacokinetics and pharmacogenetics, and biostatistics and a patient repres

53 n microscopy, morphological reconstructions, pharmacogenetics, and diffusible dye, calcium, and gluta

54 ate with advances in genetics, genomics, and pharmacogenetics; and how they can apply this knowledge

55 Therefore, we used a pharmacogenetic approach based on a virus-mediated expre

56 ulation of sleep/wakefulness and highlight a pharmacogenetic approach for the amelioration of narcole

57 d, we evaluated the feasibility of a reverse pharmacogenetic approach in a preclinical mouse model.

58 We used a pharmacogenetic approach in mice to diminish MD neuron a

59 we bypass this lethality using a noninvasive pharmacogenetic approach to inducibly perturb neuron act

60 Using a pharmacogenetic approach to model MD hypofunction, we re

61 The authors propose a new pharmacogenetic approach using ondansetron to treat seve

62 eptor exclusively activated by designer drug pharmacogenetic approach, transient inhibition of MeA PT

63 Using a pharmacogenetic approach, we find PKMzeta-antisense in h

64 Using a pharmacogenetic approach, we find that mTOR-dependent ph

65 lbumin interneurons in the mPFC with a novel pharmacogenetic approach, we restored gamma-aminobutyric

66 Using a pharmacogenetic approach, we show that the predicted Dro

67 eptor exclusively activated by designer drug pharmacogenetic approach.

68 between correlation and causality, we used a pharmacogenetic approach.

69 This study's pharmacogenetics approach strongly implicates the role o

70 ORC1 activity in the adult brain, we used a "pharmacogenetic" approach that relies on the synergistic

71 ethodologically, these results highlight how pharmacogenetic approaches allow neuron function to be q

72 Here, we used two pharmacogenetic approaches in transgenic mice to selecti

73 In the near future, pharmacogenetic approaches may facilitate personalized p

74 tions of molecular genetic, optogenetic, and pharmacogenetic approaches that overcome previous limita

75 ults highlight the requirement for stringent pharmacogenetic approaches to separate specific on-targe

76 Optogenetic and pharmacogenetic approaches were used to bidirectionally

77 and subunit-specific deletion, combined with pharmacogenetic approaches, demonstrate that amygdala ex

78 ur findings advance the understanding of the pharmacogenetic architecture of statin response.

79 REVIEW: The fields of clinical genetics and pharmacogenetics are rapidly expanding.

80 70.6% and 72.2% (P=0.47) in the standard and pharmacogenetic arms, respectively.

81 We identified a significant pharmacogenetic association at SNP rs37972, replicated i

82 The CATT and IVAN data do not support a pharmacogenetic association between the 2 VEGFR2 SNPs, r

83 A previously published study demonstrated a pharmacogenetic association between the minor alleles of

84 anisms and the clinical implications of this pharmacogenetic association remain unknown.

85 With the rapid emergence of pharmacogenetic association studies of single nucleotide

86 Pharmacogenetic association with anti-VEGF treatments ma

87 priori-selected candidate genes did not show pharmacogenetic associations above a chance level, but a

88 This study provides evidence that no pharmacogenetic associations exist between the studied V

89 Numerous pharmacogenetic associations have been discovered for im

90 unctional variants in GALR1 and to replicate pharmacogenetic associations is warranted.

91 The objectives were to replicate 3 reported pharmacogenetic associations of response in nAMD and to

92 We investigated pharmacogenetic associations of the previously studied G

93 This review highlights the germline pharmacogenetic associations that are currently being us

94 We estimated pharmacogenetic associations using high-quality phenotyp

95 The most consistent pharmacogenetic associations were observed for the corre

96 atment in neovascular AMD, suggesting strong pharmacogenetic associations with anti-VEGF treatment.

97 standing of pathogenic mechanisms underlying pharmacogenetic associations.

98 warfarin doses were prescribed according to pharmacogenetic-based algorithms for the first 5 days.

99 Pharmacogenetic-based dosing was associated with a highe

100 ational Warfarin Pharmacogenetics Consortium pharmacogenetic-based warfarin dosing algorithm (based o

101 y provides the first demonstration that host pharmacogenetics can influence therapeutic response in C

102 nes from participants of the Cholesterol and Pharmacogenetics (CAP) simvastatin clinical trial, we fo

103 ding rs7856096 to the International Warfarin Pharmacogenetic Consortium pharmacogenetic dosing algori

104 arin were obtained at International Warfarin Pharmacogenetics Consortium (IWPC) sites and the Univers

105 ntries as part of the International Warfarin Pharmacogenetics Consortium effort.

106 he recently published International Warfarin Pharmacogenetics Consortium pharmacogenetic-based warfar

107 Rapid advances in pharmacogenetics, continuous decrease in genotyping cost

108 Growing pharmacogenetic data make it evident that many opiate-re

109 vity, there are relatively little actionable pharmacogenetic data with antiplatelet agents.

110 improving patient management on the basis of pharmacogenetic data.

111 parameters, drug interaction parameters, and pharmacogenetics data have been unevenly collected in di

112 g these barriers to routine incorporation of pharmacogenetics data into clinical care.

113 Here application of a pharmacogenetic deactivation technique enabled us to inv

114 Moreover, few studies use pharmacogenetic designs that permit testing of genotype

115 Thus, NUDT15 is a pharmacogenetic determinant for thiopurine-induced leuko

116 m, and are largely independent of, the major pharmacogenetic determinants of rosuvastatin-induced LDL

117 omewide association study would reveal novel pharmacogenetic determinants of the response to inhaled

118 The effects of pharmacogenetic determinants on platelet function and ca

119 eagents and has a great potential for future pharmacogenetic diagnostics and therapy.

120 cues, personality traits, neurochemical and pharmacogenetic differences.

121 Ca(2+) channel (CaV1.1 R174W) linked to the pharmacogenetic disorder malignant hyperthermia.

122 gnant hyperthermia (MH) is potentially fatal pharmacogenetic disorder of skeletal muscle caused by in

123 Malignant hyperthermia is a pharmacogenetic disorder typically triggered by potent i

124 national Warfarin Pharmacogenetic Consortium pharmacogenetic dosing algorithm resulted in a 5.8 mg/we

125 Incorporation of this variant into pharmacogenetic dosing algorithms could improve warfarin

126 These findings may have an important pharmacogenetic effect on the development of new PAR ant

127 tion of platelet PAR1 function, but a strong pharmacogenetic effect was observed with the PAR4-specif

128 in the complement factor H (CFH) gene have a pharmacogenetics effect on the anti-vascular endothelial

129 tive of this study is to test the naltrexone pharmacogenetic effects of the Asn40Asp SNP in a sample

130 We also examined pharmacogenetic effects on cognition in the context of a

131 We found pharmacogenetic evidence for a role of 5-HT in mediating

132 Thus, pharmacogenetic evidence suggests that increased 5-HT le

133 Abcb5 alleles are pharmacogenetic factors that affect susceptibility to HI

134 ht the pharmacokinetic, pharmacodynamic, and pharmacogenetic factors that can influence analgesic, se

135 ERN and error positivity were unaffected by pharmacogenetic factors, but ERN was decoupled from beha

136 The pharmacogenetic findings also implicate the kainate rece

137 These pharmacogenetic findings are in contrast to observations

138 ar mixture of significant and nonsignificant pharmacogenetic findings that are sometimes consistent w

139 ch for PD and highlight the applicability of pharmacogenetics for enhancing cellular signaling in rep

140 Using pharmacogenetic gain- and loss-of-function studies, we f

141 Pharmacogenetics genetically re-engineers neurons to pro

142 n a few small studies relating to the use of pharmacogenetics-guided dosing in the initiation of warf

143 With its particular relevance to pharmacogenetic GWAS, SurvivalGWAS_SV will aid in the id

144 RECENT FINDINGS: Evidence now suggests that pharmacogenetics has a role in the effects of analgesic,

145 Since its first description, the field of pharmacogenetics has expanded to study a broad range of

146 Pharmacogenetics has led to the identification of severa

147 oncology, systematic application of efficacy pharmacogenetics has not been integrated into drug disco

148 Pharmacogenetics has offered compelling evidence toward

149 The third area, pharmacogenetics, has utility for some therapies today.

150 ic cells and hosts (eg, pharmacokinetics and pharmacogenetics) have pushed the cure rate of childhood

151 integration of research on neuroimaging and pharmacogenetics holds promise for improving treatment f

152 techniques, such as excitability studies and pharmacogenetics, holds promise in elucidating the under

153 Pharmacogenetics identifies the likelihood of adverse ev

154 Substance dependence can be thought of as a pharmacogenetic illness, and most likely hundreds and mo

155 cogenomics Research Network and the Clinical Pharmacogenetics Implementation Consortium are partnersh

156 ical-subcortical networks in humans, and the pharmacogenetic implications of dopamine-related genes o

157 define the role of clopidogrel and warfarin pharmacogenetics in clinical practice.

158 ew Orleans in October 2012, Optogenetics and Pharmacogenetics in Neuronal Function and Dysfunction, b

159 drug pharmacokinetics, pharmacodynamics, and pharmacogenetics in view of the absence of easily measur

160 Pharmacogenetics in warfarin clinical trials have failed

161 ement strategies based on modifier genes, to pharmacogenetics, in which individual genetic informatio

162 Pharmacogenetic inactivation of FosB-expressing neuron e

163 Selective pharmacogenetic inactivation of these neurons inhibited

164 In this article, we provide an overview of pharmacogenetics, including pharmacokinetics (PK), pharm

165 tandardized dose escalation, and to evaluate pharmacogenetics influences on PK and PD parameters.

166 Pharmacogenetic inhibition of C1 neurons bilaterally res

167 We investigated the pharmacogenetic interaction between A118G variation and

168 This study demonstrates a significant pharmacogenetic interaction between anti-IL-4 receptor a

169 nconsistent, suggesting the possibility of a pharmacogenetic interaction.

170 t effects of OPRM1 allelic variation, or for pharmacogenetic interactions between genotype and drug t

171 nctional variants on schizophrenia risk, and pharmacogenetic interactions of AKT1 with the effects on

172 esearch paradigms may be needed to translate pharmacogenetics into clinical tools.

173 In the first pharmacogenetic investigation of the efficacy of varenic

174 This is the first large pharmacogenetic investigation of the inflammatory IL-4/I

175 rs of ICS response by conducting the largest pharmacogenetic investigation to date in 2672 ICS-treate

176 A synthesis of opto- and pharmacogenetics is beginning to reveal how various inte

177 Pharmacogenetics is being used to develop personalized t

178 Pharmacogenetics is one example of how gene-environment

179 rare variants to detect and replicate novel pharmacogenetic loci.

180 on studies (GWAS) can rapidly identify novel pharmacogenetic loci.

181 ciation has identified the T gene as a novel pharmacogenetic locus for inhaled corticosteroid respons

182 Pharmacogenetic manipulation revealed the individual con

183 rkers for these neurons, and optogenetic and pharmacogenetic manipulations demonstrate that several p

184 Our study discovered novel pharmacogenetic markers and provided detailed insight in

185 interest, our finding may aid in developing pharmacogenetic markers for ADHD.

186 Three principle classes of pharmacogenetic markers have emerged: 1) pharmacokinetic

187 hesia and analgesia generated some hope that pharmacogenetics may guide anesthesiologists to provide

188 variants for monitoring treatment response (pharmacogenetics) may usher in a new era of personalized

189 Here we perform a pharmacogenetic meta-analysis of genome-wide association

190 Opto- and pharmacogenetic methods have played an important role in

191 Using pharmacogenetic methods to conditionally ablate adult ne

192 these results indicate that a comprehensive pharmacogenetic model integrating NUDT15 variants may in

193 ress and inhibition of neurogenesis in a rat pharmacogenetic model.

194 electively inhibiting these neurons with the pharmacogenetic neuromodulator hM4D.

195 II- study (n = 745, age: 8-21, USA) and the Pharmacogenetics of adrenal suppression cohort (n = 391,

196 atric Asthma Gene Environment Study, and the Pharmacogenetics of Adrenal Suppression with Inhaled Ste

197 While recent advances in pharmacogenetics of adverse drug reactions show promise,

198 Although preliminary work on the pharmacogenetics of alcoholism and its treatment has bee

199 med a meta-analysis of three cohort studies: Pharmacogenetics of Asthma Medication in Children: Medic

200 namics (colonic transit, bowel function) and pharmacogenetics of CDC in constipation-predominant irri

201 In conclusion, pharmacogenetics of CFH Y402H polymorphism may play a ro

202 rge transfusion requirements and the complex pharmacogenetics of clopidogrel may have played a role.

203 will discuss the most recent developments in pharmacogenetics of commonly used perioperative medicati

204 stigated the population pharmacokinetics and pharmacogenetics of efavirenz in 307 patients coinfected

205 eliminary results of this pilot study on the pharmacogenetics of FcgammaR and biological therapy in p

206 We summarize recent progress in the pharmacogenetics of IBD with respect to partitioning pat

207 The pharmacogenetics of methotrexate (MTX) was investigated

208 dependence; however, less is known about the pharmacogenetics of smoking cessation.

209 to describe what has heretofore been called pharmacogenetics or chemicogenetics.

210 plicated by acute ketamine administration or pharmacogenetic parvalbumin-interneuron suppression.

211 ic ligand--GPCR pairs (aka DREADDs, RASSLS, 'pharmacogenetics') permits the study of pharmacology usi

212 Pharmacogenetics (PG) could improve dosing efficiency an

213 Pharmacogenetic/pharmacogenomic (PGx) approaches to psyc

214 ts are likely to have an important effect on pharmacogenetic phenotypes.

215 l implementation of clopidogrel and warfarin pharmacogenetics possible.

216 ine learning approaches for high-dimensional pharmacogenetic prediction, and for prediction of clinic

217 This study provides a platform to evaluate pharmacogenetic predictors of response or severe adverse

218 Pharmacogenetics primarily uses genetic variation to ide

219 that this hyperkinetic disorder has a unique pharmacogenetic profile.

220 3A5 gene is likely to contribute to multiple pharmacogenetic profiles across the continent.

221 s individual susceptibility, prognostic, and pharmacogenetic profiles to maximize the efficacy and mi

222 research settings for causal gene discovery, pharmacogenetic purposes, and gene-gene and gene-environ

223 ight deprivation blocks ODP and, conversely, pharmacogenetic reduction of PV cell firing rates can ex

224 ton magnetic resonance spectroscopy data and pharmacogenetic response to stimulant medication.

225 treated subjects, demonstrating a successful pharmacogenetic screen in MS.

226 In the realm of cardiovascular pharmacogenetics, significant advances have identified m

227 of optical activation and cell type-specific pharmacogenetic silencing in vitro, we found that dendri

228 on cell-type-specific optical activation and pharmacogenetic silencing in vitro, we show that tempora

229 Pharmacogenetic silencing of VMHvl reversibly inhibits i

230 Here, using optogenetic activation and pharmacogenetic silencing, we found that type 6 bipolar

231 an ancestry who participated in one of three pharmacogenetic smoking cessation clinical trials and we

232 Moreover, optogenetic as well as pharmacogenetic specific activation of the vHipp-mPFC pa

233 Here, we used a pharmacogenetic strategy to decrease mediodorsal thalami

234 was performed on data from three genome-wide pharmacogenetic studies (the Genome-Based Therapeutic Dr

235 Pharmacogenetic studies aiming to personalize the treatm

236 Currently, pharmacogenetic studies are at an impasse as the low pre

237 Pharmacogenetic studies can be conducted in multicenter

238 To date, pharmacogenetic studies have been primarily performed in

239 Importance: Previous pharmacogenetic studies have shown the prognostic impact

240 his assay may be useful to complement future pharmacogenetic studies in asthma.

241 Pharmacogenetic studies in larger cohorts are needed to

242 hese data may provide proof-of-principle for pharmacogenetic studies in schizophrenia.

243 NP-drug response association dataset for 650 pharmacogenetic studies involving 257 drugs in this upda

244 Pharmacogenetic studies of admixed ethnic groups have be

245 nally, the authors discuss unique aspects of pharmacogenetic studies that may distinguish them from s

246 Although most pharmacogenetic studies to date have assessed the associ

247 Prior pharmacogenetic studies usually measure exposure via sin

248 Additional, larger pharmacogenetic studies would help to validate these res

249 s: in vivo pharmacokinetics studies, in vivo pharmacogenetic studies, in vivo drug interaction studie

250 Concerning pharmacogenetic studies, no association was found for th

251 ed populations, which can be used for future pharmacogenetic studies.

252 ance of maximizing adherence to treatment in pharmacogenetic studies.

253 Pharmacogenetics studies are the platform for discoverin

254 rom non-responders via genetic predictors in pharmacogenetics studies have not met their anticipated

255 ssion Network [DeNT] study; N=332), and 3) a pharmacogenetic study (the Genome-Based Therapeutic Drug

256 This pharmacogenetic study evaluated the impact of high-risk

257 ant that samples be collected and stored for pharmacogenetic study in future clinical trials.

258 We conducted a multicenter observational and pharmacogenetic study of 200 patients with DLE treated w

259 mine treatment in a prospective double-blind pharmacogenetics study in first-generation Mexican Ameri

260 ed by Genetic Haplotype Markers) study was a pharmacogenetics study of statin efficacy and safety.

261 This is the largest and most comprehensive pharmacogenetics study to date examining clinical respon

262 Design, Setting, and Participants: Pharmacogenetic substudy of 1545 patients who participat

263 ity to HIT, but it is likely that additional pharmacogenetic susceptibility factors will be discovere

264 intracellular signaling, as well as through pharmacogenetic targeting.

265 encephalogram (EEG) power spectrum using the pharmacogenetic technique, the 'designer receptors exclu

266 Here we used pharmacogenetic techniques to show a causal relation bet

267 Pharmacogenetic techniques used on tumour and host tissu

268 s to feeding behaviour using optogenetic and pharmacogenetic techniques.

269 ghlight which variants and in which contexts pharmacogenetic testing can be implemented by practicing

270 Pharmacogenetic testing combined with monitoring of hair

271 ng may be beneficial, the data today support pharmacogenetic testing for certain variants on an indiv

272 In contrast, pharmacogenetic testing for HLA-B*1502 before carbamazep

273 One blood sample was collected for pharmacogenetic testing from each patient who elected to

274 lso presents the current recommendations for pharmacogenetic testing in clinical practice and explore

275 ical trials will determine if routine use of pharmacogenetic testing may be beneficial, the data toda

276 tes that they stand to benefit the most from pharmacogenetic testing.

277 abeling in 2007 to suggest, but not mandate, pharmacogenetic testing.

278 ves for translating clopidogrel and warfarin pharmacogenetic tests to clinical practice.

279 Pharmacogenetics, though presently confined to the asses

280 search into the role of pharmacokinetics and pharmacogenetics to guide appropriate dosing of obese pa

281 extension of previous studies of naltrexone pharmacogenetics to individuals of Asian descent, an eth

282 ngs, two-photon microscopy, optogenetics and pharmacogenetics to show how repeated cocaine exposure a

283 olecular genetics along with optogenetic and pharmacogenetic tools for perturbing neuron function hav

284 Anatomic and pharmacogenetic tools were used to identify the pathways

285 etically encoded anatomical, optogenetic and pharmacogenetic tools, we demonstrate that activation of

286 ls represent a promising novel target in the pharmacogenetic treatment of alcohol and drug addiction.

287 ogy of the disease could help development of pharmacogenetic treatments.

288 ) project, a partially randomized open-label pharmacogenetic trial.

289 vergent findings reported by recent warfarin pharmacogenetic trials.

290 examine the association between clinical and pharmacogenetic variables and statin concentrations in p

291 ative or opiate doses and pharmacokinetic or pharmacogenetic variables, such as drug plasma levels (e

292 ne uncertain variants in cancer genes (98%), pharmacogenetic variants (89%), and recessive carrier mu

293 to review the association data for the major pharmacogenetic variants associated with commonly used c

294 nificant racial differences in prevalence of pharmacogenetic variants were observed, although small s

295 perturbation enables identification of true pharmacogenetic variants.

296 is table may potentially increase the use of pharmacogenetic warfarin dosing in clinical practice; ho

297 gly popular, predominantly in the context of pharmacogenetics, where the survival endpoint could be d

298 Ultimately, pharmacogenetics will give providers the options for imp

299 Future utility for pharmacogenetics will wax or wane depending on the natur

300 Optogenetics with microbial opsin genes, and pharmacogenetics with designer receptors, represent pote